Povetacicept for Primary Membranous Nephropathy
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 176 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
This trial is looking for people diagnosed with primary membranous nephropathy. Participants will evaluate the safety and effectiveness of a treatment called povetacicept.
You may be able to join if
- I have been diagnosed with primary membranous nephropathy.
You may not be able to join if
- I have a hypersensitivity to the treatment or its ingredients.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Loading trial locations…